An international team of researchers examined differential gene expression in blood samples from patients infected during the West African outbreak.
A team led by University of Toronto researchers developed the signature as a clinical assay that could predict treatment response.
Researchers uncovered snoRNA differences in tumors from breast cancer cases with better or worse overall survival or recurrence-free survival.
Researchers saw abbreviated overall survival times in estrogen receptor-positive metastatic breast cancer patients with ESR1 mutations in their cell-free DNA.
An algorithm called SURVIV tapped TCGA RNA sequence data to find exon-skipping events associated with better or worse outcomes in breast and other cancers.
Researchers used the 21-gene expression assay to find individuals at lowest risk of breast cancer recurrence, who were spared adjuvant chemotherapy.
The company's EndoPredict test, launched in 2011, uses cancer gene expression profiling in combination with standard prognostic factors to assess relapse risk in breast cancer patients.
Though cancer experts noted many tests under MEDCAC review were developed to be predictive of treatment response, CMS maintained the meeting's focus on the prognostic context.
A team scrutinized use of the 21-gene recurrence assay with the help of data on more than 70,800 individuals diagnosed with breast cancer between 2005 and 2009.
The study demonstrated that the company's DecisionDx-Melanoma assay better predicts the risk of metastasis in patients with localized disease than clinical staging alone.
Vivek Murthy is no longer the surgeon general of the US, the Associated Press reports.
People around the globe took to the streets to support science — some with signs.
Parents who learn of their increased genetic risk of disease also contend with telling their children about theirs, the New York Times writes.
In PLOS this week: loci linked to body mass index measurements, long non-coding RNA expression and urothelial carcinoma prognosis, and more.